Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-Exo-A600 in Mild to Moderate Alzheimer's Disease
NCT07457125Phase 2Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of CB-Exo-A600 in Alzheimer's disease (AD), sponsored by Xuanwu Hospital. Started May 2026; status: recruiting.
02
Drugs
CB-Exo-A600
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07457125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07457125.